SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing renewed market attention driven by its institutional-grade post-quantum security features and its classification as a digital commodity. While the community remains divided between long-term holders optimistic about its real-world asset tokenization potential and bears focused on historic price performance, active discussions highlight a surge in trading volume and increased social dominance.

U.S. Gold Corp. engages in the exploration of gold properties. It has properties in CK Gold Project, Wyoming, Challis Gold Project, Idaho, and Keystone, Nevada. The company was founded in 1967 and is headquartered in Elko, NV.

U.S. Gold Corp

U.S. Gold Corp ($USAU) is trending as investors focus on its near-term catalysts, including its upcoming inclusion in the Russell index and the highly anticipated completion of a feasibility study for the CK Gold Project. While community members highlight the project's de-risking and potential for institutional inflows, discussions are also dominated by concerns over the high volume of automated accounts pumping the stock.

Norfolk Southern Corp. is a transportation company, which engages in the rail transportation of raw materials, intermediate products, and finished goods. The company also transports overseas freight through several Atlantic and Gulf Coast ports. Its services include property leases and sales, wire line or pipeline and fiber optics projects, access property, managing private crossings, promoting businesses with signboards, and natural resource management. The company was founded on July 23, 1980, and is headquartered in Atlanta, GA.

Norfolk Southern Corp.

Norfolk Southern is trending as investors react to a significant accounting shift involving a multi-million dollar lease renewal in Atlanta, which the company has reclassified as a finance lease. Community discourse is currently split between analyzing the impact of this increased balance sheet leverage on the company's long-term financial health and ongoing discussions regarding operational challenges and broader rail sector sentiment.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is seeing significant community engagement as investors debate its long-term potential following recent integrations and post-quantum security developments. While some participants express frustration over price volatility and token supply concerns, others are actively accumulating the asset, citing the project's institutional partnerships and foundational role in the evolving AI agent sector.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing heightened investor attention following a series of clinical wins and regulatory milestones in its oncology and immunology portfolios, including strong performance data for its multiple myeloma franchise. While the community remains focused on these pipeline developments and growth catalysts, discussion is balanced by ongoing monitoring of significant talc-related legal liabilities and potential regulatory impacts on pricing.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render is experiencing a surge in community interest and market activity as investors highlight its pivotal role in the decentralized AI compute and DePIN sectors. The sentiment is heavily bolstered by ongoing discussions regarding its real-world utility, integration with industry giants, and anticipation for future network growth.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as community members debate its potential to decouple from Bitcoin and outperform as a peer-to-peer electronic cash system. Discussions are heavily focused on its resilience, upcoming protocol upgrades, and potential for a breakout as participants speculate on it reclaiming its position as a market leader.

Agree Realty Corp. is a real estate investment trust, which engages in the ownership, acquisition, development, and management of retail properties net leased to industry tenants. It focuses on the long-term, fee simple ownership of properties net leased to national and large regional retailers. The company was founded by Richard Agree in 1971 and is headquartered in Royal Oak, MI.

Agree Realty Corp.

Agree Realty (ADC) is trending as investors monitor its resilient performance in the net-lease REIT sector, with the community frequently debating its growth trajectory and dividend quality relative to peers like Realty Income. Discussions are anchored in the firm's strategic management, robust portfolio quality, and recent insider buying activity, which have bolstered investor sentiment during broader market volatility.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is currently trending due to intense market speculation surrounding potential high-stakes M&A activity, with the company aggressively positioning its $100 billion investment strategy to bolster its obesity and oncology pipelines. While the stock has faced recent price volatility, the community is actively debating the likelihood of a major acquisition to compete with industry giants, alongside ongoing discussions about the company's long-term growth and its strategic focus on immunology.

Maul Coin

Maul Coin is gaining momentum as community members actively rally to build a long-term foundation, emphasizing transparency and active creator involvement to distinguish the project from typical pump-and-dump schemes. The community is focused on increasing holder count, driving social media engagement, and pushing for official chart verification to fuel organic growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA

Hennion & Walsh Asset Management Inc. bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 308,457 shares of the com...

SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA

SG Americas Securities LLC boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 2,271.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 781,474 shares of the company's stock a...

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5% - Should You Buy?

Taysha Gene Therapies (NASDAQ:TSHA) Trading 8.5% Higher - Here's Why...

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%  - Time to Sell?

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9% - Should You Sell...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have given a buy...

Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Taysha Gene Therapies from a "sell" rating to a "hold" rating in a research report on Saturday...

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC

Needham & Company LLC increased their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday...

Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Chardan Capital reaffirmed a "buy" rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday...

Taysha Gene Therapies Q4 Earnings Call Highlights

Taysha Gene Therapies (NASDAQ:TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a...

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Earnings Beat...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$4.37
Prev Close	$4.31
Open	$4.18
Dividend Yield	0.00%
50-Day Moving Average	$4.56
Beta	1.66
Avg. Volume	3.13M
PE Ratio	-12.12

52-Week High	$6.02
52-Week Low	$1.05
Market Capitalization	$1.24B
EPS (Annual)	-$0.3409
Price to Book	5.04
Revenue Per Employee	$98,717.17

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TSHA News

TSHATaysha Gene Therapies Inc